{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T07:40:37Z","timestamp":1791877237727,"version":"4.3.4"},"reference-count":112,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003141","name":"Secretar\u00eda de Ciencia, Humanidades, Tecnolog\u00eda e Innovaci\u00f3n","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003141","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jpharmsci.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.xphs.2025.104108","type":"journal-article","created":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T00:31:30Z","timestamp":1764117090000},"page":"104108","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Biowaiver monograph for immediate-release solid oral dosage forms: Amlodipine besylate"],"prefix":"10.1016","volume":"115","author":[{"given":"Porfirio","family":"de la Cruz-Cruz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5618-3318","authenticated-orcid":false,"given":"Mauricio A.","family":"Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0642-0033","authenticated-orcid":false,"given":"Jos\u00e9 Trinidad","family":"P\u00e9rez-Urizar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertil","family":"Abrahamsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo","family":"Cristofoletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2957-6287","authenticated-orcid":false,"given":"Atsushi","family":"Kambayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehul","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6875-3899","authenticated-orcid":false,"given":"Alan","family":"Parr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5274-4314","authenticated-orcid":false,"given":"James E.","family":"Polli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinod P.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2519-1179","authenticated-orcid":false,"given":"Naseem","family":"Charoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sirajunisa","family":"Talath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Dressman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Langguth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.xphs.2025.104108_bib0001","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1161\/HYPERTENSIONAHA.120.15026","article-title":"2020 International society of hypertension global hypertension practice guidelines","volume":"75","author":"Unger","year":"2020","journal-title":"Hypertension"},{"issue":"5","key":"10.1016\/j.xphs.2025.104108_bib0002","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1038\/s41440-024-01622-w","article-title":"The WHO global report 2023 on hypertension warning the emerging hypertension burden in globe and its treatment strategy","volume":"47","author":"Kario","year":"2024","journal-title":"Hypertens Res"},{"issue":"1","key":"10.1016\/j.xphs.2025.104108_bib0003","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1080\/07853890.2022.2044510","article-title":"Comparison between the world health organization (WHO) and international society of hypertension (ISH) guidelines for hypertension","volume":"54","author":"Nugroho","year":"2022","journal-title":"Ann Med"},{"key":"10.1016\/j.xphs.2025.104108_bib0008","unstructured":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use Ich Harmonised Guideline. Biopharmaceutics classification system-based biowaivers M9.; 2019. Accessed August 10, 2025. chrome-extension:\/\/efaidnbmnnnibpcajpcglclefindmkaj\/https:\/\/database.ich.org\/sites\/default\/files\/M9_Guideline_Step4_2019_1116.pdf."},{"issue":"1","key":"10.1016\/j.xphs.2025.104108_bib0009","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.xphs.2021.09.031","article-title":"Biowaiver monograph for immediate-release solid oral dosage forms: sitagliptin phosphate monohydrate","volume":"111","author":"Charoo","year":"2022","journal-title":"J Pharm Sci"},{"issue":"2","key":"10.1016\/j.xphs.2025.104108_bib0010","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.xphs.2023.11.005","article-title":"Biowaiver monograph for immediate-release solid oral dosage forms: isavuconazonium sulfate","volume":"113","author":"Plano","year":"2024","journal-title":"J Pharm Sci"},{"issue":"4","key":"10.1016\/j.xphs.2025.104108_bib0011","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.xphs.2022.12.021","article-title":"Biowaiver monograph for immediate-release solid oral dosage forms: levocetirizine dihydrochloride","volume":"112","author":"Charoo","year":"2023","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.xphs.2025.104108_bib0012","doi-asserted-by":"crossref","unstructured":"The United States Pharmacopeia. Amlodipine besylate tablets.; 2021. doi:10.31003\/USPNF_M3575_08_01.","DOI":"10.31003\/USPNF_M3575_08_01"},{"issue":"12","key":"10.1016\/j.xphs.2025.104108_bib0013","doi-asserted-by":"crossref","first-page":"5279","DOI":"10.1021\/cg101127z","article-title":"Solid forms of amlodipine besylate: physicochemical, structural, and thermodynamic characterization","volume":"10","author":"Koradia","year":"2010","journal-title":"Cryst Growth Des"},{"key":"10.1016\/j.xphs.2025.104108_bib0014","first-page":"31","article-title":"Amlodipine besylate","volume":"37","author":"Ananchenko","year":"2012"},{"key":"10.1016\/j.xphs.2025.104108_bib0015","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1023\/A:1016067130634","article-title":"Physico-chemical characterization of hydrated and anhydrous crystal forms of amlodipine besylate","volume":"68","author":"Rollinger","year":"2002","journal-title":"J Therm Anal Calorim"},{"key":"10.1016\/j.xphs.2025.104108_bib0016","doi-asserted-by":"crossref","unstructured":"The United States Pharmacopeia. Amlodipine besylate. Published online August 1, 2023. doi:10.31003\/USPNF_M3570_06_01.","DOI":"10.31003\/USPNF_M3570_06_01"},{"issue":"11","key":"10.1016\/j.xphs.2025.104108_bib0017","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1055\/a-0611-4927","article-title":"Does GastroPlus support similarity and dissimilarity factors of in vitro-in vivo prediction in biowaiver studies? A lower strength amlodipine as a model drug","volume":"68","author":"Zaid","year":"2018","journal-title":"Drug Res"},{"issue":"6","key":"10.1016\/j.xphs.2025.104108_bib0018","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1002\/pdi.1264","article-title":"Amlodipine","volume":"25","author":"Williamson","year":"2008","journal-title":"Pract Diabetes Int"},{"issue":"7618","key":"10.1016\/j.xphs.2025.104108_bib0019","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/nature19102","article-title":"Structural basis for inhibition of a voltage-gated Ca2+ channel by Ca2+ antagonist drugs","volume":"537","author":"Tang","year":"2016","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.xphs.2025.104108_bib0020","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1093\/eurheartj\/ehy504","article-title":"Anti-anginal drugs-beliefs and evidence: systematic review covering 50 years of medical treatment","volume":"40","author":"Ferrari","year":"2019","journal-title":"Eur Heart J"},{"issue":"13","key":"10.1016\/j.xphs.2025.104108_bib0021","doi-asserted-by":"crossref","DOI":"10.1161\/01.CIR.102.13.1503","article-title":"Effect of Amlodipine on the progression of atherosclerosis and the occurrence of clinical events","volume":"102","author":"Pitt","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.xphs.2025.104108_bib0027","unstructured":"FDA. Highlights of prescribing information. www.fda.gov\/medwatch."},{"issue":"1","key":"10.1016\/j.xphs.2025.104108_bib0029","article-title":"Pharmacokinetics and pharmacodynamics of amlodipine","volume":"80","author":"Abernethy Darrell","year":"1992","journal-title":"Cardiology"},{"issue":"1","key":"10.1016\/j.xphs.2025.104108_bib0030","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.1097\/00005344-199117001-00020","article-title":"An update on the safety of amlodipine","volume":"17","author":"Osterloh Ian","year":"1991","journal-title":"J Cardiovasc Pharmacol"},{"issue":"7","key":"10.1016\/j.xphs.2025.104108_bib0031","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00717-18","article-title":"Analysis of clinical drug-drug interaction data to predict magnitudes of uncharacterized interactions between antiretroviral drugs and comedications","volume":"62","author":"Stader","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"10.1016\/j.xphs.2025.104108_bib0032","article-title":"Pharmacokinetics of amlodipine in renal impairment","volume":"12","author":"Laher","year":"1988","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.xphs.2025.104108_bib0033","doi-asserted-by":"crossref","DOI":"10.1136\/openhrt-2016-000473","article-title":"Amlodipine in hypertension: a first-line agent with efficacy for improving blood pressure and patient outcomes","volume":"3","author":"Fares","year":"2016","journal-title":"Open Heart"},{"key":"10.1016\/j.xphs.2025.104108_bib0034","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/j.1365-2125.1986.tb02874.x","article-title":"The pharmacokinetics of amlodipine in healthy volunteers after single intravenous and oral doses and after 14 repeated oral doses given once daily","volume":"22","author":"Faulkner","year":"1986","journal-title":"Br J clin Pharmac"},{"issue":"5","key":"10.1016\/j.xphs.2025.104108_bib0035","doi-asserted-by":"crossref","DOI":"10.1016\/S0735-6757(98)90011-0","article-title":"Amlodipine overdose causes prolonged calcium channel blocker toxicity","volume":"16","author":"Adams","year":"1997","journal-title":"Am J Emerg Med"},{"issue":"3","key":"10.1016\/j.xphs.2025.104108_bib0036","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S1353-1131(03)00043-9","article-title":"A fatal case of amlodipine poisoning","volume":"10","author":"Johansen","year":"2003","journal-title":"J Clin Forensic Med"},{"issue":"7-8","key":"10.1016\/j.xphs.2025.104108_bib0037","doi-asserted-by":"crossref","DOI":"10.1177\/106002809703100708","article-title":"Case reports amlodipine overdose","volume":"31","author":"Stanek","year":"1997","journal-title":"Ann Pharmacother"},{"issue":"5","key":"10.1016\/j.xphs.2025.104108_bib0038","doi-asserted-by":"crossref","first-page":"365","DOI":"10.5005\/jp-journals-10071-23423","article-title":"Severe amlodipine toxicity: a case rescued with extracorporeal membrane oxygenation","volume":"24","author":"Sutar","year":"2020","journal-title":"Indian J Crit Care Med"},{"issue":"11","key":"10.1016\/j.xphs.2025.104108_bib0039","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1055\/a-0611-4927","article-title":"Does GastroPlus support similarity and dissimilarity factors of in vitro-in vivo prediction in Biowaiver studies? A lower strength amlodipine as a model drug","volume":"68","author":"Zaid","year":"2018","journal-title":"Drug Res"},{"key":"10.1016\/j.xphs.2025.104108_bib0041","article-title":"Center for drug evaluation and research. Applicatio number 19-787\/S-007","year":"1996","journal-title":"Med Rev(s)"},{"issue":"1","key":"10.1016\/j.xphs.2025.104108_bib0042","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1161\/HYPERTENSIONAHA.120.16061","article-title":"Plasma trough concentrations of antihypertensive drugs for the assessment of treatment adherence: a meta-analysis","volume":"77","author":"Groenland","year":"2021","journal-title":"Hypertension"},{"issue":"1","key":"10.1016\/j.xphs.2025.104108_bib0043","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1161\/HYPERTENSIONAHA.120.15038","article-title":"Clinical applicability of monitoring antihypertensive drug levels in blood","volume":"76","author":"Peeters","year":"2020","journal-title":"Hypertension"},{"issue":"4","key":"10.1016\/j.xphs.2025.104108_bib0045","first-page":"207","article-title":"Bioavailability file: amlodipine","volume":"36","author":"Mustafa Sinan","year":"2011","journal-title":"J Pharm Sci"},{"issue":"6","key":"10.1016\/j.xphs.2025.104108_bib0046","first-page":"519","article-title":"Physicochemical stability of compounded amlodipine besylate suspensions in PCCA base, SuspendIt","volume":"23","author":"Graves","year":"2019","journal-title":"Int J Pharm Compd"},{"key":"10.1016\/j.xphs.2025.104108_bib0047","first-page":"1","article-title":"Formulations of amlodipine: a review","author":"Sheraz","year":"2016","journal-title":"J Pharm"},{"issue":"6","key":"10.1016\/j.xphs.2025.104108_bib0048","doi-asserted-by":"crossref","DOI":"10.1016\/j.clinthera.2005.06.011","article-title":"Clinic blood pressure responses tO two amlodipine salt formulations, adipate and besylate, in adult Korean patients with mild to moderate hypertension: a multicenter, randomized, double-blind, parallel-group, 8-week comparison","volume":"27","author":"Lee","year":"2005","journal-title":"Clin Ther"},{"issue":"1","key":"10.1016\/j.xphs.2025.104108_bib0049","doi-asserted-by":"crossref","first-page":"66","DOI":"10.5414\/CP202045","article-title":"Pharmacokinetic comparison of amlodipine adipate\/valsartan and amlodipine besylate\/valsartan as fixed-dose combinations in healthy volunteers","volume":"53","author":"Nam","year":"2015","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"5","key":"10.1016\/j.xphs.2025.104108_bib0050","doi-asserted-by":"crossref","DOI":"10.1016\/S0149-2918(04)90071-9","article-title":"Randomized, open-label, two-period crossover comparison of the pharmacokinetic and pharmacodynamic properties of two amlodipine formulations in healthy adult male Korean subjects","volume":"26","author":"Park","year":"2004","journal-title":"Clin Ther"},{"issue":"9","key":"10.1016\/j.xphs.2025.104108_bib0051","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1016\/j.clinthera.2007.09.018","article-title":"Results of a phase III, 8-week, multicenter, prospective, randomized, double-blind, parallel-group clinical trial to assess the effects of amlodipine camsylate versus amlodipine besylate in Korean adults with mild to moderate hypertension","volume":"29","author":"Kim","year":"2007","journal-title":"Clin Ther"},{"key":"10.1016\/j.xphs.2025.104108_bib0052","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.2147\/DDDT.S113891","article-title":"Comparisons of the pharmacokinetics and tolerability of fixed-dose combinations of amlodipine besylate\/losartan and amlodipine camsylate\/losartan in healthy subjects: a randomized, open-label, single-dose, two-period, two-sequence crossover study","volume":"10","author":"Choi","year":"2016","journal-title":"Drug Des Dev Ther"},{"issue":"4","key":"10.1016\/j.xphs.2025.104108_bib0053","doi-asserted-by":"crossref","DOI":"10.1016\/j.clinthera.2006.04.008","volume":"28","author":"Hong","year":"2006","journal-title":"Clin Ther"},{"key":"10.1016\/j.xphs.2025.104108_bib0054","doi-asserted-by":"crossref","first-page":"2811","DOI":"10.2147\/DDDT.S82820","article-title":"Bioequivalence evaluation of two amlodipine salts, besylate and orotate, each in a fixed-dose combination with olmesartan in healthy subjects","volume":"9","author":"Lee","year":"2015","journal-title":"Drug Des Dev Ther"},{"issue":"3","key":"10.1016\/j.xphs.2025.104108_bib0055","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1021\/op900283z","article-title":"A novel method for resolution of amlodipine","volume":"14","author":"Gotrane","year":"2010","journal-title":"Org Process Res Dev"},{"key":"10.1016\/j.xphs.2025.104108_bib0056","unstructured":"Qu H, Savolainen MR, Christensen LP, Rantanen JT. Solubility and transformation of the solid forms of amlodipene besilate to its free base.; 2011."},{"issue":"7","key":"10.1016\/j.xphs.2025.104108_bib0057","doi-asserted-by":"crossref","first-page":"2896","DOI":"10.1002\/jps.22509","article-title":"Phase transformations of amlodipine besylate solid forms","volume":"100","author":"Koradia","year":"2011","journal-title":"J Pharm Sci"},{"issue":"23","key":"10.1016\/j.xphs.2025.104108_bib0058","doi-asserted-by":"crossref","first-page":"6107","DOI":"10.1016\/j.bmc.2004.09.004","article-title":"Ionization, lipophilicity, and molecular modeling to investigate permeability and other biological properties of amlodipine","volume":"12","author":"Caron","year":"2004","journal-title":"Bioorg Med Chem"},{"issue":"10","key":"10.1016\/j.xphs.2025.104108_bib0059","doi-asserted-by":"crossref","DOI":"10.1002\/jps.2600841008","article-title":"Partitioning of ionizing molecules between aqueous buffers and phospholipid vesicles","volume":"84","author":"Austin","year":"1995","journal-title":"J Pharm Sci"},{"issue":"1","key":"10.1016\/j.xphs.2025.104108_bib0060","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1021\/js980206m","article-title":"Ionization constants and distribution coefficients of phenothiazines and calcium channel antagonists determined by a pH-metric method and correlation with calculated partition coefficients","volume":"88","author":"Franke","year":"1999","journal-title":"J Pharm Sci"},{"issue":"6","key":"10.1016\/j.xphs.2025.104108_bib0061","doi-asserted-by":"crossref","first-page":"724","DOI":"10.3109\/03639040903460438","article-title":"The influence of chirality, physicochemical properties, and permeation enhancers on the transdermal permeation of amlodipine across rat skin","volume":"36","author":"Zeng","year":"2010","journal-title":"Drug Dev Ind Pharm"},{"key":"10.1016\/j.xphs.2025.104108_bib0062","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/0378-5173(95)04412-4","article-title":"Formulation development of a transdermal drug delivery system for amlodipine base","volume":"133","author":"Mcdaid","year":"1996","journal-title":"Int J Pharm"},{"key":"10.1016\/j.xphs.2025.104108_bib0063","first-page":"31","article-title":"Amlodipine besylate","volume":"37","author":"Ananchenko","year":"2012"},{"issue":"3","key":"10.1016\/j.xphs.2025.104108_bib0064","doi-asserted-by":"crossref","first-page":"485","DOI":"10.3109\/03639045.2015.1104347","article-title":"Solid-state characterization of felodipine-soluplus amorphous solid dispersions","volume":"42","author":"Lu","year":"2016","journal-title":"Drug Dev Ind Pharm"},{"issue":"4","key":"10.1016\/j.xphs.2025.104108_bib0065","article-title":"Enhancement of water solubility and dissolution rate of felodipine using modified \u03b2-cyclodextrins","volume":"4","author":"Acholu","year":"2013","journal-title":"J Glob Trends Pharm Sci"},{"issue":"7","key":"10.1016\/j.xphs.2025.104108_bib0066","first-page":"3060","article-title":"Formulation of nicerdipine hydrochloride inclusion complex for dissolution enhancement","volume":"9","author":"Makwana","year":"2018","journal-title":"Int J Pharm Sci Res"},{"issue":"2","key":"10.1016\/j.xphs.2025.104108_bib0067","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics15020446","article-title":"Development of an oral liquid formulation of nicardipine hydrochloride compounded with simple excipients for the treatment of pediatric hypertension","volume":"15","author":"Cavelier","year":"2023","journal-title":"Pharmaceutics"},{"issue":"10","key":"10.1016\/j.xphs.2025.104108_bib0068","doi-asserted-by":"crossref","first-page":"3289","DOI":"10.1002\/jps.24560","article-title":"Biowaiver monographs for immediate-release solid oral dosage forms: Nifedipine","volume":"104","author":"Gajendran","year":"2015","journal-title":"J Pharm Sci"},{"issue":"4","key":"10.1016\/j.xphs.2025.104108_bib0069","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1208\/s12248-016-9918-x","article-title":"Effect of gastric fluid volume on the in vitro dissolution and in vivo absorption of BCS class II drugs: a case study with nifedipine","volume":"18","author":"Nader","year":"2016","journal-title":"AAPS J"},{"key":"10.1016\/j.xphs.2025.104108_bib0070","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.carbpol.2013.08.046","article-title":"HPMC as a potential enhancer of nimodipine biopharmaceutical properties via ball-milled solid dispersions","volume":"99","author":"Riekes","year":"2014","journal-title":"Carbohydr Polym"},{"key":"10.1016\/j.xphs.2025.104108_bib0071","doi-asserted-by":"crossref","first-page":"119","DOI":"10.2147\/IJN.S186899","article-title":"Preparation and characterization of nimodipine-loaded nanostructured lipid systems for enhanced solubility and bioavailability","volume":"14","author":"Teng","year":"2019","journal-title":"Int J Nanomed"},{"issue":"34","key":"10.1016\/j.xphs.2025.104108_bib0072","first-page":"21476","article-title":"Improvement of in vitro dissolution of the poor water-soluble amlodipine drug by solid dispersion with irradiated polyvinylpyrrolidone","volume":"5","author":"Ghobashy","year":"2020","journal-title":"Am Chem Soc Omega"},{"issue":"10","key":"10.1016\/j.xphs.2025.104108_bib0073","first-page":"3958","article-title":"In vitro studies of amlodipine besylate tablet and comparison with foreign brand leader IN Nepal","volume":"4","author":"Pant","year":"2013","journal-title":"Int J Pharm Sci Res"},{"issue":"6","key":"10.1016\/j.xphs.2025.104108_bib0074","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1211\/jpp.58.6.0013","article-title":"Intestinal permeability and excretion into bile control the arrival of amlodipine into the systemic circulation after oral administration","volume":"58","author":"Rau\u0161l","year":"2010","journal-title":"J Pharm Pharmacol"},{"key":"10.1016\/j.xphs.2025.104108_bib0075","doi-asserted-by":"crossref","DOI":"10.1590\/s2175-979020200004181083","article-title":"Effects of experimental conditions on solubility measurements for BCS classification in order to improve the biowaiver guidelines","volume":"57","author":"Monteiro","year":"2021","journal-title":"Braz J Pharm Sci"},{"issue":"8","key":"10.1016\/j.xphs.2025.104108_bib0076","doi-asserted-by":"crossref","first-page":"930","DOI":"10.3109\/10837450.2013.840847","article-title":"The impact of chirality on the development of robust and stable tablet formulation of (S-) amlodipine besylate","volume":"19","author":"Had\u017eidedi\u0107","year":"2014","journal-title":"Pharm Dev Technol"},{"issue":"1","key":"10.1016\/j.xphs.2025.104108_bib0077","first-page":"706","article-title":"Formulation and evaluation of mouth dissolving tablet containing amlodipine besylate solid dispersion","volume":"2","author":"Dahima","year":"2010","journal-title":"Int J Chemtech Res"},{"issue":"5","key":"10.1016\/j.xphs.2025.104108_bib0078","first-page":"356","article-title":"The effect of ion pairing on the skin permeation of amlodipine","volume":"63","author":"Jiang","year":"2008","journal-title":"Pharmazie"},{"issue":"3","key":"10.1016\/j.xphs.2025.104108_bib0079","article-title":"Enhancement of dissolution properties of amlodipine besylate using liquisolid technique","volume":"5","author":"Kaur","year":"2013","journal-title":"Int J Pharm Pharm Sci"},{"key":"10.1016\/j.xphs.2025.104108_bib0080","unstructured":"Center for drug evaluation and research application number: 212895Orig1s000 product quality review(s)."},{"issue":"3","key":"10.1016\/j.xphs.2025.104108_bib0082","doi-asserted-by":"crossref","first-page":"299","DOI":"10.2478\/v10007-008-0012-5","article-title":"Stability of amlodipine besylate and atenolol in multi-component tablets of mono-layer and bi-layer types","volume":"58","author":"Aryal","year":"2008","journal-title":"Acta Pharm"},{"issue":"4","key":"10.1016\/j.xphs.2025.104108_bib0083","first-page":"755","article-title":"Formulation and bioequivalence of two valsartan\/amlodipine immediate release tablets after a single oral administration","volume":"27","author":"Zaid","year":"2014","journal-title":"Pak J Pharm Sci"},{"issue":"3","key":"10.1016\/j.xphs.2025.104108_bib0084","doi-asserted-by":"crossref","first-page":"480","DOI":"10.5530\/ijper.53.3.80","article-title":"Formulation and stability studies of fast disintegrating tablets of amlodipine besylate","volume":"53","author":"Furqan Ahsan","year":"2019","journal-title":"Indian J Pharm Educ Res"},{"issue":"9","key":"10.1016\/j.xphs.2025.104108_bib0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2023.e19993","article-title":"A new stability-indicating HPLC-UV method for determination of amlodipine besylate and its impurities in drug substance","volume":"9","author":"Jeelani","year":"2023","journal-title":"Heliyon"},{"issue":"1","key":"10.1016\/j.xphs.2025.104108_bib0086","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1081\/PDT-120027414","article-title":"Amlodipine besylate-excipients interaction in solid dosage form","volume":"9","author":"Abdoh","year":"2004","journal-title":"Pharm Dev Technol"},{"issue":"11","key":"10.1016\/j.xphs.2025.104108_bib0087","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1002\/j.1552-4604.1988.tb03119.x","article-title":"Amlodipine pharmacokinetics in healthy volunteers","volume":"28","author":"Williams","year":"1988","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.xphs.2025.104108_bib0088","doi-asserted-by":"crossref","first-page":"22","DOI":"10.2165\/00003088-199222010-00003","article-title":"Clinical pharmacokinetics of amlodipine","volume":"22","author":"Elliott","year":"1992","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"10.1016\/j.xphs.2025.104108_bib0089","doi-asserted-by":"crossref","first-page":"65","DOI":"10.5414\/CP202449","article-title":"Bioequivalence study of an extemporaneously prepared oral solution of amlodipine suitable for use in pediatric patients compared to commercial tablets","volume":"54","author":"van de Vossen","year":"2016","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.xphs.2025.104108_bib0090","doi-asserted-by":"crossref","first-page":"245","DOI":"10.3109\/00498258809041660","article-title":"Metabolism and kinetics of amlodipine in man","volume":"18","author":"Beresford","year":"1988","journal-title":"Xenobiotica"},{"issue":"1","key":"10.1016\/j.xphs.2025.104108_bib0091","doi-asserted-by":"crossref","DOI":"10.1111\/j.1527-3466.1990.tb00427.x","article-title":"Amlodipine","volume":"8","author":"Burges","year":"1990","journal-title":"Cardiovasc Drug Rev"},{"key":"10.1016\/j.xphs.2025.104108_bib0092","unstructured":"Trinidad P\u00e9rez Urizar J, De La Cruz Cruz P, Lopes L, Gomide R, Dutra Duque M. Evaluation of the dissolution behavior of the lysosomotropic drug amlodipine using physiologically based biopharmaceutics modeling (PBBM)."},{"issue":"10","key":"10.1016\/j.xphs.2025.104108_bib0094","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1177\/0091270006291097","article-title":"Effect of food on the bioavailability of amlodipine besylate\/atorvastatin calcium combination tablet","volume":"46","author":"Chung","year":"2006","journal-title":"J Clin Pharmacol"},{"issue":"5","key":"10.1016\/j.xphs.2025.104108_bib0095","first-page":"229","article-title":"The influence of food on the pharmacokinetics of amlodipine and losartan after single-dose of its compound tablets in healthy Chinese subjects","volume":"64","author":"Lv","year":"2014","journal-title":"Drug Res"},{"issue":"6","key":"10.1016\/j.xphs.2025.104108_bib0096","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1002\/cpdd.131","article-title":"Effect of food on the oral bioavailability of amlodipine\/valsartan and amlodipine\/valsartan\/hydrochlorothiazide fixed dose combination tablets in healthy subjects","volume":"3","author":"Sunkara","year":"2014","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"4","key":"10.1016\/j.xphs.2025.104108_bib0097","article-title":"Effect of food on bioavailability of amlodipine in Indian population","volume":"4","author":"Patel","year":"2015","journal-title":"Int J Adv Pharm Biol Chem"},{"issue":"8","key":"10.1016\/j.xphs.2025.104108_bib0098","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1211\/0022357043941","article-title":"Concentration dependency of modulatory effect of amlodipine on P-glycoprotein efflux activity of doxorubicin \u2014 a comparison with tamoxifen","volume":"56","author":"Darvari","year":"2010","journal-title":"J Pharm Pharmacol"},{"key":"10.1016\/j.xphs.2025.104108_bib0099","first-page":"164","article-title":"Method considerations for Caco-2 permeability assessment in the biopharmaceutics classification system","volume":"28","author":"Tolle-Sander","year":"2002","journal-title":"Pharmacopeial Forum"},{"key":"10.1016\/j.xphs.2025.104108_bib0100","doi-asserted-by":"crossref","first-page":"811","DOI":"10.2147\/DDDT.S126035","article-title":"Fixed-dose combination orally disintegrating tablets to treat cardiovascular disease: formulation, in vitro characterization and physiologically based pharmacokinetic modeling to assess bioavailability","volume":"11","author":"Dennison","year":"2017","journal-title":"Drug Des Dev Ther"},{"issue":"4","key":"10.1016\/j.xphs.2025.104108_bib0101","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1007\/s11095-008-9789-7","article-title":"Grapefruit juice and its constituents augment colchicine intestinal absorption: potential hazardous interaction and the role of P-glycoprotein","volume":"26","author":"Dahan","year":"2009","journal-title":"Pharm Res"},{"issue":"3","key":"10.1016\/j.xphs.2025.104108_bib0102","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1007\/s11095-008-9771-4","article-title":"Concentration-dependent effect of naringin on intestinal absorption of \u03b21-adrenoceptor antagonist talinolol mediated by p-glycoprotein and organic anion transporting polypeptide (oatp)","volume":"26","author":"Shirasaka","year":"2009","journal-title":"Pharm Res"},{"issue":"1","key":"10.1016\/j.xphs.2025.104108_bib0103","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1124\/jpet.109.159756","article-title":"Species difference in the effect of grapefruit juice on intestinal absorption of talinolol between human and rat","volume":"332","author":"Shirasaka","year":"2010","journal-title":"J Pharmacol Exp Ther"},{"issue":"33","key":"10.1016\/j.xphs.2025.104108_bib0104","article-title":"Medicinal importance of grapefruit juice and its interaction with various drugs","volume":"6","author":"Kiani","year":"2007","journal-title":"Nutr J"},{"issue":"10","key":"10.1016\/j.xphs.2025.104108_bib0105","doi-asserted-by":"crossref","first-page":"2808","DOI":"10.1002\/jps.20975","article-title":"Grapefruit juice-drug interactions: Grapefruit juice and its components inhibit P-glycoprotein (ABCB1) mediated transport of talinolol in caco-2 cells","volume":"96","author":"De Castro","year":"2007","journal-title":"J Pharm Sci"},{"issue":"3","key":"10.1016\/j.xphs.2025.104108_bib0106","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.lfs.2004.06.015","article-title":"Effects of grapefruit juice on the multidrug transporter P-glycoprotein in the human proximal tubular cell line HK-2","volume":"76","author":"Romiti","year":"2004","journal-title":"Life Sci"},{"issue":"5","key":"10.1016\/j.xphs.2025.104108_bib0107","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1046\/j.1365-2125.2000.00283.x","article-title":"Lack of effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of amlodipine","volume":"50","author":"Vincent","year":"2000","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"10.1016\/j.xphs.2025.104108_bib0108","doi-asserted-by":"crossref","first-page":"204","DOI":"10.22159\/ajpcr.2018.v11i6.24971","article-title":"Quantitative determination of amlodipine from CACO-2 cell monolayers by high-performance liquid chromatography\u2013mass spectrometry\/mass spectrometry","volume":"11","author":"Logoyda","year":"2018","journal-title":"Asian J Pharm Clin Res"},{"issue":"7","key":"10.1016\/j.xphs.2025.104108_bib0109","article-title":"The metabolism and pharmacokinetics of amlodipine in humans and animals","volume":"12","author":"Stopher","year":"1998","journal-title":"J Cardiovadcular Pharmacol"},{"issue":"2","key":"10.1016\/j.xphs.2025.104108_bib0110","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1002\/chir.20738","article-title":"Stereoselective plasma protein binding of amlodipine","volume":"22","author":"Maddi","year":"2010","journal-title":"Chirality"},{"issue":"2","key":"10.1016\/j.xphs.2025.104108_bib0111","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1124\/dmd.113.055400","article-title":"Amlodipine metabolism in human liver microsomes and roles of CYP3A4\/5 in the dihydropyridine dehydrogenation","volume":"42","author":"Zhu","year":"2014","journal-title":"Drug Metab Dispos"},{"issue":"2","key":"10.1016\/j.xphs.2025.104108_bib0112","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/BF00609197","article-title":"Pharmacokinetics of Amlodipine in renal impairment","volume":"36","author":"Doyle","year":"1989","journal-title":"Eur J Clin Pharmacol"},{"issue":"9","key":"10.1016\/j.xphs.2025.104108_bib0114","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1002\/bdd.282","article-title":"Amlodipine bioequivalence study: quantification by liquid chromatography coupled to tandem mass spectrometry","volume":"22","author":"De Nucci","year":"2001","journal-title":"Biopharm Drug Dispos"},{"issue":"9","key":"10.1016\/j.xphs.2025.104108_bib0115","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.4314\/tjpr.v17i9.1","article-title":"Comparative in vitro dissolution and in vivo bioavailability of commercial amlodipine tablets","volume":"17","author":"Jung-Cook","year":"2018","journal-title":"Trop J Pharm Res"},{"issue":"4","key":"10.1016\/j.xphs.2025.104108_bib0116","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.clinthera.2009.04.013","article-title":"Pharmacokinetics and bioequivalence evaluation of two formulations of 10-mg amlodipine besylate: an open-label, single-dose, randomized, two-way crossover study in healthy Chinese male volunteers","volume":"31","author":"Liu","year":"2009","journal-title":"Clin Ther"},{"issue":"7","key":"10.1016\/j.xphs.2025.104108_bib0117","first-page":"462","article-title":"Pharmacokinetics and bioequivalence study of a generic amlodipine tablet formulation in healthy male volunteers","volume":"57","author":"Sailer","year":"2007","journal-title":"Arzneimittelforschung"},{"issue":"6","key":"10.1016\/j.xphs.2025.104108_bib0118","doi-asserted-by":"crossref","DOI":"10.1002\/jcla.23228","article-title":"Evaluation of pharmacokinetics and safety with bioequivalence of Amlodipine in healthy Chinese volunteers: bioequivalence study findings","volume":"34","author":"Wang","year":"2020","journal-title":"J Clin Lab Anal"},{"key":"10.1016\/j.xphs.2025.104108_bib0121","unstructured":"Fda. Center for drug evaluation and research."},{"issue":"2","key":"10.1016\/j.xphs.2025.104108_bib0125","doi-asserted-by":"crossref","first-page":"6","DOI":"10.14227\/DT280221P6","article-title":"Evaluation of in vitro equivalence of commonly available generic brands of amlodipine tablets in Saudi Arabia under biowaiver conditions","volume":"28","author":"Incecayir","year":"2021","journal-title":"Dissolut Technol"},{"issue":"2","key":"10.1016\/j.xphs.2025.104108_bib0126","article-title":"Assessment of pharmaceutical quality control and equivalence of various brands of amlodipine besylate (5 MG) tablets available in the Pakistani market under biowaiver conditions","volume":"6","author":"FEROZ","year":"2014","journal-title":"Int J Pharm Pharm Sci"},{"issue":"4","key":"10.1016\/j.xphs.2025.104108_bib0127","doi-asserted-by":"crossref","DOI":"10.14227\/DT280421PGC1","article-title":"Quality attributes and in vitro bioequivalence of Amlodipine (5 mg) tablets in Ica, Peru","volume":"28","author":"Garc\u00eda","year":"2021","journal-title":"Dissolut Technol"},{"issue":"2","key":"10.1016\/j.xphs.2025.104108_bib0128","first-page":"265","article-title":"Equivalence of two generic brands of amlodipine besylate under Biowaiver conditions","volume":"4","author":"Olusola Akinleye","year":"2012","journal-title":"Int J Pharm Pharm Sci"},{"issue":"1","key":"10.1016\/j.xphs.2025.104108_bib0129","first-page":"13","article-title":"Interplay of solubility and dissolution in dosage form development","volume":"2","author":"Semalty","year":"2014","journal-title":"Int J Pharm Drug Anal"},{"issue":"8","key":"10.1016\/j.xphs.2025.104108_bib0130","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1016\/j.xphs.2020.04.011","article-title":"Evaluation of differences in dosage form performance of generics using BCS-based biowaiver specifications and biopharmaceutical modeling\u2013Case examples amoxicillin and doxycycline","volume":"109","author":"Hofs\u00e4ss","year":"2020","journal-title":"J Pharm Sci"},{"issue":"5","key":"10.1016\/j.xphs.2025.104108_bib0131","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics11050215","article-title":"In silico prediction of plasma concentrations of fluconazole capsules with different dissolution profiles and bioequivalence study using population simulation","volume":"11","author":"Duque","year":"2019","journal-title":"Pharmaceutics"},{"issue":"1","key":"10.1016\/j.xphs.2025.104108_bib0132","first-page":"45","article-title":"Amlodipine-a third generation dihydropyridine calcium antagonist","volume":"2","author":"Steffen","year":"1999","journal-title":"J Clin Basic Cardiol"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354925005623?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354925005623?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T05:28:23Z","timestamp":1773898103000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354925005623"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":112,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S0022354925005623"],"URL":"https:\/\/doi.org\/10.1016\/j.xphs.2025.104108","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biowaiver monograph for immediate-release solid oral dosage forms: Amlodipine besylate","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xphs.2025.104108","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Inc. on behalf of American Pharmacists Association.","name":"copyright","label":"Copyright"}],"article-number":"104108"}}